Skip to Content

Press Releases and Events

PRESS RELEASES


Press Release | May 22, 2026

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

READ MORE

Press Release | May 7, 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

READ MORE

Press Release | April 27, 2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

READ MORE

Press Release | April 8, 2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

READ MORE

Press Release | March 26, 2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

READ MORE

Press Release | February 26, 2026

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

READ MORE

Press Release | February 5, 2026

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

READ MORE

Press Release | January 26, 2026

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

READ MORE

Press Release | January 22, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE

Press Release | January 12, 2026

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE

1 / 24